Schedule 13G Filing by Commodore Capital LP and Others for Alto Neuroscience, Inc.

Commodore Capital LP, along with Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson, filed a Schedule 13G with the SEC, disclosing their ownership in Alto Neuroscience, Inc. As of October 20, 2025, the group beneficially owns 3,190,267 shares of Common Stock, representing 9.8% of the outstanding shares. This includes 1,653,913 shares of Common Stock and 1,536,354 shares that can be acquired through the exercise of a pre-funded warrant. The filing indicates that the securities were not acquired for the purpose of influencing the control of the issuer. The filing was made under Rule 13d-1(c) and signed by Michael Kramarz and Robert Egen Atkinson.